Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
1–7 In particular, an association between some of the connective-tissue diseases and Hashimoto's thyroiditis (lymphadenoid goiter) has recently seemed likely. 6,8,9 Many reports of this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback